Mark G. Kris, MD, discusses 1 of the major topics of discussion from the 15th Annual New York Lung Cancers Symposium, among other areas of focus at the meeting.
Mark G. Kris, MD
Articles by Mark G. Kris, MD
Mark G. Kris, MD, discusses treatment options for <em>MET</em>-mutant non–small cell lung cancer.
Mark G. Kris, MD, discusses the importance of delaying relapse in patients with <em>EGFR</em>-positive non–small cell lung cancer. He shares the significance of the findings from the phase III RELAY trial, where the goal was to delay the time to relapse by adding ramucirumab to erlotinib.
Mark G. Kris, MD, discusses what is most important in treating patients with lung cancer today.
Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Mark G. Kris, MD, William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan-Kettering Cancer Center, gives an overview of current guidelines for molecular testing in lung cancer.
Latest Updated Articles
Expert Highlights Key Topics of Discussion at the 15th Annual New York Lung Cancers SymposiumPublished: November 7th 2020 | Updated:
Ramucirumab Used to Delay Relapse Following EGFR TKIs in EGFR+ NSCLCPublished: July 12th 2019 | Updated:
An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung CancersPublished: April 9th 2018 | Updated:
Advice for Treating Patients With Lung CancerPublished: December 7th 2018 | Updated:
Treatment Options in MET-Mutant NSCLCPublished: November 10th 2019 | Updated:
Guidelines for Molecular Testing in Lung CancerPublished: November 15th 2013 | Updated: